Home World News FDA Approves Lurbinectedin in Combination with Atezolizumab or Atezolizumab and Hyaluronidase-tqjs for... World News FDA Approves Lurbinectedin in Combination with Atezolizumab or Atezolizumab and Hyaluronidase-tqjs for Extensive Stage SCLC By Ogkologos - October 16, 2025 416 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Lung Cancer Death Rates Among Women in Europe Are Finally Levelling... January 19, 2026 FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk... July 31, 2025 Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients... June 4, 2025 Inseparable Couples Dies 33 Hours Apart After 68 Years Of Marriage:... December 5, 2019 Load more HOT NEWS Patient Guide in Bladder Cancer Now Available Also in French Combination of Nivolumab and Ipilimumab Yields Better Outcomes Compared to Ipilimumab... More Immunotherapy Options Approved for Treating Endometrial Cancer Pharmacokinetically Guided Dose Optimisation of Oral Targeted Therapies Reduces the Proportion...